Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 3 6Phase 1 5Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 3Metastatic Castration-Resistant Prostate Cancer 1Hormone Treatment-naïve Participants With Prostate Cancer 1Endometriosis 1Adenocarcinoma 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × relugolix × Genitourinary × Clear all
NCT06631521 2026-02-05

Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer

AdventHealth

Phase 1 Recruiting
30 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT05679388 2024-09-19

A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients

University of Chicago

Phase 1 Terminated
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT02141659 2018-11-19

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Takeda

Phase 1 Completed
43 enrolled 23 charts
Genitourinary

Hormone Treatment-naïve Participants With Prostate Cancer

NCT02093390 2016-06-06

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
40 enrolled 23 charts
Genitourinary

Endometriosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡